PMC:7361557
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 564-571 | Body_part | denotes | glucose | http://purl.org/sig/ont/fma/fma82743 |
| T2 | 971-977 | Body_part | denotes | kidney | http://purl.org/sig/ont/fma/fma7203 |
| T3 | 1421-1426 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
| T4 | 1427-1434 | Body_part | denotes | glucose | http://purl.org/sig/ont/fma/fma82743 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 971-977 | Body_part | denotes | kidney | http://purl.obolibrary.org/obo/UBERON_0002113 |
| T2 | 1421-1426 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 3 | 69-77 | Species | denotes | patients | Tax:9606 |
| 4 | 21-29 | Disease | denotes | diabetes | MESH:D003920 |
| 5 | 90-98 | Disease | denotes | COVID‐19 | MESH:C000657245 |
| 9 | 153-161 | Species | denotes | patients | Tax:9606 |
| 10 | 167-175 | Disease | denotes | COVID‐19 | MESH:C000657245 |
| 11 | 234-242 | Disease | denotes | diabetes | MESH:D003920 |
| 18 | 405-413 | Species | denotes | patients | Tax:9606 |
| 19 | 444-452 | Species | denotes | patients | Tax:9606 |
| 20 | 516-524 | Species | denotes | patients | Tax:9606 |
| 21 | 564-571 | Chemical | denotes | glucose | MESH:D005947 |
| 22 | 396-404 | Disease | denotes | COVID‐19 | MESH:C000657245 |
| 23 | 435-443 | Disease | denotes | COVID‐19 | MESH:C000657245 |
| 36 | 865-873 | Species | denotes | patients | Tax:9606 |
| 37 | 1007-1015 | Species | denotes | patients | Tax:9606 |
| 38 | 1036-1044 | Species | denotes | patients | Tax:9606 |
| 39 | 774-782 | Disease | denotes | COVID‐19 | MESH:C000657245 |
| 40 | 852-856 | Disease | denotes | died | MESH:D003643 |
| 41 | 895-907 | Disease | denotes | inflammation | MESH:D007249 |
| 42 | 933-949 | Disease | denotes | myocardia injury | MESH:D014947 |
| 43 | 951-965 | Disease | denotes | hepatic injury | MESH:D056486 |
| 44 | 971-984 | Disease | denotes | kidney injury | MESH:D058186 |
| 45 | 1004-1006 | Disease | denotes | DM | MESH:D009223 |
| 46 | 1027-1035 | Disease | denotes | COVID‐19 | MESH:C000657245 |
| 47 | 1199-1212 | Disease | denotes | hyperglycemia | MESH:D006943 |
| 53 | 1356-1364 | Species | denotes | patients | Tax:9606 |
| 54 | 1524-1532 | Species | denotes | patients | Tax:9606 |
| 55 | 1427-1434 | Chemical | denotes | glucose | MESH:D005947 |
| 56 | 1347-1355 | Disease | denotes | COVID‐19 | MESH:C000657245 |
| 57 | 1545-1553 | Disease | denotes | COVID‐19 | MESH:C000657245 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 14-29 | Disease | denotes | type 2 diabetes | http://purl.obolibrary.org/obo/MONDO_0005148 |
| T2 | 21-29 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
| T3 | 90-98 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T4 | 167-175 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T5 | 234-242 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
| T6 | 396-404 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T7 | 435-443 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T8 | 774-782 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T9 | 895-907 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
| T10 | 943-949 | Disease | denotes | injury | http://purl.obolibrary.org/obo/MONDO_0021178 |
| T11 | 959-965 | Disease | denotes | injury | http://purl.obolibrary.org/obo/MONDO_0021178 |
| T12 | 978-984 | Disease | denotes | injury | http://purl.obolibrary.org/obo/MONDO_0021178 |
| T13 | 1004-1006 | Disease | denotes | DM | http://purl.obolibrary.org/obo/MONDO_0005015|http://purl.obolibrary.org/obo/MONDO_0016367 |
| T15 | 1027-1035 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T16 | 1199-1212 | Disease | denotes | hyperglycemia | http://purl.obolibrary.org/obo/MONDO_0002909 |
| T17 | 1347-1355 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T18 | 1545-1553 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 184-185 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T2 | 795-798 | http://purl.obolibrary.org/obo/CLO_0053001 | denotes | 114 |
| T3 | 817-818 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T4 | 836-838 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
| T5 | 921-931 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
| T6 | 971-977 | http://purl.obolibrary.org/obo/UBERON_0002113 | denotes | kidney |
| T7 | 971-977 | http://www.ebi.ac.uk/efo/EFO_0000927 | denotes | kidney |
| T8 | 971-977 | http://www.ebi.ac.uk/efo/EFO_0000929 | denotes | kidney |
| T9 | 1071-1072 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T10 | 1421-1426 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| T11 | 1421-1426 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 14-29 | Phenotype | denotes | type 2 diabetes | http://purl.obolibrary.org/obo/HP_0005978 |
| T2 | 1199-1212 | Phenotype | denotes | hyperglycemia | http://purl.obolibrary.org/obo/HP_0003074 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 895-907 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
| T2 | 909-920 | http://purl.obolibrary.org/obo/GO_0050817 | denotes | coagulation |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-98 | Sentence | denotes | The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID‐19 |
| T2 | 99-107 | Sentence | denotes | Xu et al |
| T3 | 109-117 | Sentence | denotes | Abstract |
| T4 | 118-126 | Sentence | denotes | Abstract |
| T5 | 128-138 | Sentence | denotes | Background |
| T6 | 139-280 | Sentence | denotes | Although T2DM patients with COVID‐19 develop a more severe condition compared to those without diabetes, the mechanisms for this are unknown. |
| T7 | 281-376 | Sentence | denotes | Moreover, the impact of treatment with anti‐hyperglycemic drugs and glucocorticoids is unclear. |
| T8 | 378-385 | Sentence | denotes | Methods |
| T9 | 386-593 | Sentence | denotes | From 1584 COVID‐19 patients, 364 severe/critical COVID‐19 patients with clinical outcome were enrolled for the final analysis and patients without pre‐existing T2DM but elevated glucose levels were excluded. |
| T10 | 594-741 | Sentence | denotes | Epidemiological data were obtained and clinical‐status evaluation carried out to assess the impact of T2DM and its management on clinical outcomes. |
| T11 | 743-750 | Sentence | denotes | Results |
| T12 | 751-835 | Sentence | denotes | Of 364 enrolled severe COVID‐19 inpatients, 114 (31.3%) cases had a history of T2DM. |
| T13 | 836-1016 | Sentence | denotes | 27(23.7%) cases died in T2DM patients, who had more severe inflammation, coagulation activation, myocardia injury, hepatic injury, and kidney injury, compared with non‐DM patients. |
| T14 | 1017-1284 | Sentence | denotes | In severe COVID‐19 patients with T2DM, we demonstrate a higher risk of all‐cause fatality with glucocorticoid treatment (Adjusted HR, 3.61; 95%CI, 1.14‐11.46; P = 0.029), and severe hyperglycemia (FPG ≥11.1 mmol/L) (Adjusted HR, 11.86; 95%CI, 1.21‐116.44; P = 0.034). |
| T15 | 1286-1297 | Sentence | denotes | Conclusions |
| T16 | 1298-1407 | Sentence | denotes | T2DM status aggravated the clinical condition of COVID‐19 patients and increased their critical illness risk. |
| T17 | 1408-1554 | Sentence | denotes | Poor fasting blood glucose (≥ 11.1 mmol/L) and glucocorticoid treatment are associated with poor prognosis for T2DM patients with severe COVID‐19. |
| T18 | 1555-1594 | Sentence | denotes | This article is protected by copyright. |
| T19 | 1595-1615 | Sentence | denotes | All rights reserved. |